ChemBriefRevolution Medicines gets FDA nod for targeted pancreatic cancer drug
The FDA approved Revolution Medicines' Rasonque for metastatic pancreatic cancer, boosting median survival to 13.2 months versus 6.7 months on standard therapy. This first-in-class RAS inhibitor addre
reuters · 2026-08-26 08:08 UTC